DE60108130T2 - Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten - Google Patents

Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten Download PDF

Info

Publication number
DE60108130T2
DE60108130T2 DE60108130T DE60108130T DE60108130T2 DE 60108130 T2 DE60108130 T2 DE 60108130T2 DE 60108130 T DE60108130 T DE 60108130T DE 60108130 T DE60108130 T DE 60108130T DE 60108130 T2 DE60108130 T2 DE 60108130T2
Authority
DE
Germany
Prior art keywords
tartaric acid
methyl
substituted
amine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60108130T
Other languages
German (de)
English (en)
Other versions
DE60108130D1 (de
Inventor
Maurice Gary DULL
Jean-Pierre Leconte
Humayun Stratford KABIR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of DE60108130D1 publication Critical patent/DE60108130D1/de
Application granted granted Critical
Publication of DE60108130T2 publication Critical patent/DE60108130T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60108130T 2000-07-14 2001-07-11 Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten Expired - Fee Related DE60108130T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/616,743 US6432954B1 (en) 2000-07-14 2000-07-14 Pharmaceutical compositions and methods for use
US616743 2000-07-14
PCT/US2001/021872 WO2002005798A2 (en) 2000-07-14 2001-07-11 Pharmaceutical compositions for treating neurological disorders

Publications (2)

Publication Number Publication Date
DE60108130D1 DE60108130D1 (de) 2005-02-03
DE60108130T2 true DE60108130T2 (de) 2006-02-23

Family

ID=24470778

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60108130T Expired - Fee Related DE60108130T2 (de) 2000-07-14 2001-07-11 Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten

Country Status (16)

Country Link
US (1) US6432954B1 (enExample)
EP (1) EP1311265B1 (enExample)
JP (1) JP2004509851A (enExample)
CN (2) CN1468100A (enExample)
AT (1) ATE285773T1 (enExample)
AU (2) AU2290902A (enExample)
BR (1) BR0112130A (enExample)
CA (1) CA2415901A1 (enExample)
DE (1) DE60108130T2 (enExample)
HU (1) HUP0301553A3 (enExample)
IL (3) IL153577A0 (enExample)
NO (1) NO20030155L (enExample)
NZ (1) NZ523606A (enExample)
PL (1) PL360532A1 (enExample)
WO (1) WO2002005798A2 (enExample)
ZA (1) ZA200300135B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
AU2005235414A1 (en) * 2004-04-21 2005-11-03 Basf Aktiengesellschaft Fungicidal mixtures
UA88792C2 (ru) * 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
WO2007134038A2 (en) * 2006-05-09 2007-11-22 Astrazeneca Ab Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
WO2008034041A2 (en) * 2006-09-15 2008-03-20 Astrazeneca Ab Therapeutic combinations
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
KR20100052490A (ko) * 2007-07-31 2010-05-19 타가셉트 인코포레이티드 (2ｓ)-(4ｅ)-ｎ-메틸-5-(3-(5-이소프로폭시피리딘)일)-4-펜텐-2-아민의 경피투여
JP2013528601A (ja) 2010-05-20 2013-07-11 アストラゼネカ・アクチエボラーグ アリール置換オレフィン系アミンの新規な製造方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1409551A (en) 1972-04-14 1975-10-08 Allen & Hanburys Ltd Cyclopent a indene derivatives
US4528290A (en) 1984-01-30 1985-07-09 Eli Lilly And Company Stimulating dopamine D-1 receptors
GB8606254D0 (en) 1986-03-13 1986-04-16 Wyeth John & Brother Ltd Substituted pyrimidoindoles
FR2664600B1 (fr) 1990-07-16 1994-09-02 Rhone Poulenc Sante Nouveau sel derive de la dialcoylaminoalcoyl-sulfonyl-26 pristinamycine iib.
US5278176A (en) * 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
AU3470495A (en) * 1994-09-14 1996-03-29 H. Lundbeck A/S Carbamoyloxy amine compounds
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
JP3603177B2 (ja) * 1998-03-26 2004-12-22 参天製薬株式会社 新規ウレア誘導体
ES2150353B1 (es) * 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
DE69919537T2 (de) * 1998-06-16 2005-09-08 Targacept, Inc. Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DE10032456A1 (de) * 2000-07-04 2002-01-31 Lohmann Therapie Syst Lts Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen
US6743812B1 (en) * 2000-07-14 2004-06-01 Targacept, Inc. Pharmaceutical compositions and methods for use

Also Published As

Publication number Publication date
CN1468100A (zh) 2004-01-14
NO20030155D0 (no) 2003-01-13
DE60108130D1 (de) 2005-02-03
IL192287A0 (en) 2008-12-29
EP1311265A2 (en) 2003-05-21
BR0112130A (pt) 2003-09-02
WO2002005798A3 (en) 2003-03-13
WO2002005798A2 (en) 2002-01-24
ZA200300135B (en) 2004-04-06
ATE285773T1 (de) 2005-01-15
EP1311265B1 (en) 2004-12-29
PL360532A1 (en) 2004-09-06
IL153577A (en) 2009-07-20
US6432954B1 (en) 2002-08-13
IL153577A0 (en) 2003-07-06
NZ523606A (en) 2004-12-24
CA2415901A1 (en) 2002-01-24
JP2004509851A (ja) 2004-04-02
CN1680326A (zh) 2005-10-12
AU2002222909B2 (en) 2005-12-15
NO20030155L (no) 2003-03-13
HUP0301553A2 (hu) 2003-08-28
AU2290902A (en) 2002-01-30
HUP0301553A3 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
US6492399B1 (en) Pharmaceutical compositions and methods for use
DE69919537T2 (de) Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten
DE60109924T2 (de) Heteroaryldiazabicycloalkane als liganden für den nikotinischen acetylcholin-rezeptor
US6455554B1 (en) Oxopyridinyl pharmaceutical compositions and methods for use
US20080249142A1 (en) Hydroxybenzoate salts of metanicotine compounds
US8778978B2 (en) Hydroxybenzoate salts of metanicotine compounds
WO2000075110A1 (en) Pharmaceutical compositions and methods for use
JP2000509041A (ja) 中枢神経系障害の予防及び治療のための医薬組成物
DE69535131T2 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE60108130T2 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
US7045538B2 (en) Compounds capable of activating cholinergic receptors
US6743812B1 (en) Pharmaceutical compositions and methods for use
DE69907894T2 (de) Azatricyclo[3.3.1.1]decanderivate und diese enthaltende phrmazeutische zubereitungen
DE69910993T2 (de) Azatrizyclische verbindungen
AU2002222909A1 (en) Pharmaceutical compositions for treating neurological disorders
DE69924979T2 (de) Behandlung von chronischen schmerzen
DE69825879T2 (de) Pharmazeutische zusammensetzungen welche aryl-substituierte olefinische amin-verbindungen enthalten
US7060826B2 (en) Compounds capable of activating cholinergic receptors
AU2006202005B2 (en) Pharmaceutical compositions for treating neurological disorders
US20080214628A1 (en) Compounds Capable of Activating Cholinergic Receptors
US20030087915A1 (en) Pharmaceutical compositions and methods for use
KR100568997B1 (ko) 중추신경계질환의예방및치료를위한약제학적조성물
HK1082255A (en) Pharmaceutical compositions and methods for use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee